Dr. Guillaume Lemercier

•Successfully developed more than 80 different cell-based, biomolecular and enzymatic screening assays for different classes of therapeutic targets (Receptor pathways, Immune checkpoints, Enzymes, GPCR, ion channels...) including hit characterization and optimization. •Involved in all external collaborations as key representative of the biology group in joint meetings. •Directly managed 3-5 associates in their daily work in assay development, biophysical methods, phage-display and protein expression.

• Achieved objective: Identification of active small molecules hitting target proteins with high potency and selectivity for the treatment of infectious diseases. • Successfully developed automated high-throughput assays using several screening technologies for various targets (kinase, protease, phosphatase and others), • Ran HTS, confirmed positives, generated dose response curves, molecular MOA and optimized hits in close collaboration with the medicinal chemists.

• Successfully developed an innovative yeast two-hybrid method (Split-Trp) to study protein-protein or protein-small molecule interactions. The technology was licensed to the DualSystems biotech. • Developed a new method for the covalent and specific cross-linking of proteins with small molecule substrates in living mammalian cells. This technique offers the opportunity to induce and sense protein-protein interactions, yielding important insight into their function.

• From the identification of genes of interest to the in vivo model of mutant parasites, I used various approaches to biochemically and biologically characterize acidocalcisome-associated enzymes and to study acidocalcisome polyphosphate metabolism.

• Generated and screened a yeast genomic DNA library to identify genes of unknown function which confer null mutant phenotypes. This work was done during my pre-doctoral research.

• Validation of a new adjuvant to enhance the immune response to a respiratory syncitial virus vaccine.

Acidocalcisomes and polyphosphate metabolism, new trypanosomatid therapeutic targets.

Identification of genes of unknown function which confer null mutant phenotypes in yeast.

Biotechnology, Biochemistry, Cell Biology, Molecular Biology, Immunology